Obesity has ceased to be a purely aesthetic concern and has emerged as the greatest public health crisis of the 21st century. In every medical consultation, in every family, obesity is no longer a secondary issue—it has become a central concern.
At the beginning of 2026, figures confirm the worst projections: according to the World Obesity Atlas, more than 900 million adults are already living with obesity worldwide [1]. By 2030, it is expected that 3 billion people will be overweight or obese—an inflection point that threatens the sustainability of healthcare systems.
In fact, by 2035, the global cost associated with overweight and obesity could exceed USD 4.32 trillion annually (nearly 3% of global GDP), effectively undermining the sustainability of health systems [1].
In our region, adult prevalence exceeds 60% in several countries, while childhood obesity is rising at alarming rates, compromising the future of new generations. This condition is driving an increasing number of cases of type 2 diabetes, hypertension, and at least 13 types of cancer at ever younger ages [2][3]. The economic impact is equally devastating: associated costs threaten to suffocate healthcare budgets.
The scientific debate is settled: obesity is not a failure of willpower nor simply the result of “eating too much and moving too little.” This recognition not only transforms clinical practice but also compels health systems and society to rethink their policies and attitudes.
The WHO recognizes obesity as a chronic, complex, and multifactorial disease resulting from the interaction of genetic, neurobiological, behavioral, environmental, and social factors [4][5][6]. This paradigm shift is critical to:
In recent years, the therapeutic field has undergone a revolution. GLP-1 receptor agonists, such as semaglutide and tirzepatide, have achieved weight reductions of 15% to 22%—levels previously attainable only through bariatric surgery [7][8]. In addition, these drugs provide cardiorenal benefits, reducing the risk of heart attacks and strokes. However, access to these advances remains limited in many countries in the region, underscoring the need for public policies that ensure treatment equity.
Yet innovation is not a “magic solution”: it must be integrated into comprehensive care models that include behavioral changes and specialized medical support to ensure the sustainability of outcomes.
An individual-focused approach is insufficient if the environment remains obesogenic (referring to everything that promotes the development of obesity—environments or factors that encourage weight gain and hinder the adoption of healthy habits). Countries that have managed to stabilize their rates have implemented robust multisectoral strategies:
We cannot treat a systemic disease with isolated solutions. A comprehensive approach requires:
Only coordinated action among governments, the private sector, healthcare professionals, and civil society will make it possible to reverse this trend and protect the health of future generations.